November 7, 2025
Certara Reports Third Quarter 2025 Financial Results
Updates Full Year 2025 Financial GuidanceRADNOR, Pa., Nov. 06, 2025 (GLOBE NEWSWIRE) — Certara, Inc. (Nasdaq: CERT), a global leader…
Pharmaceuticals, Biotechnology and Life Sciences
Updates Full Year 2025 Financial GuidanceRADNOR, Pa., Nov. 06, 2025 (GLOBE NEWSWIRE) — Certara, Inc. (Nasdaq: CERT), a global leader…
– CHS-114, a highly selective Treg depleter, clinical program expanded to include colorectal cancer – – Q3 2025 ending cash,…
Third-Quarter Net Revenue of $4.8 million; Robust Growth Drives 35% Increase in Net Revenue and Fourth Consecutive Quarter of Profitability…
– CX-2051 Phase 1 data update on track for Q1 2026 – – CX-2051 Phase 1b CRC combination study with…
MENLO PARK, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) — BillionToOne, Inc. (Nasdaq: BLLN), a molecular diagnostics company with a mission…
SUNNYVALE, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) — BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the…
Presentation will highlight preclinical data supporting the potential of WVE-007 (INHBE GalNAc-siRNA) as a unique approach for the treatment of…
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Nov. 04, 2025 (GLOBE NEWSWIRE) — HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13)…
NEW YORK, Nov. 04, 2025 (GLOBE NEWSWIRE) — Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory…
Oral Presentation on Saturday to Highlight Interim Safety and Efficacy Results from the MyPEAK™-1 Phase 1b/2a Clinical Trial in Adults with…